Ambion was the previously RNA-involved company acquired by Applied Biosystems in 2006 - that then merged with Invitrogen to form Life Technologies, itself since 2014 part of Thermo Fisher Scientific (NYSE: TMO). Ambion, Inc. is organized around the development and supply of RNA-based life science research and molecular biology products. The firm provides kits, enzymes, and reagents for life science research and drug development and develops products for handling, preserving, isolating, detecting, and measuring RNA in the areas of molecular biology, cell biology, microbiology, drug discovery, and genomics. Addressing the in vitro diagnostic and pharmaceutical processing industries, Ambio also offers microRNA-related products; and siRNA reagents used to study mechanisms of gene expression that leads to advances in human healthcare.
